Pure Global
NCT06099652

Evaluation of 611 in Chinese Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease

A Multi-Centered, Randomized, Double-Blinded, Placebo-Controlled Phase II Clinical Trial, to Evaluate the Efficacy and Safety of 611 in Chinese Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease.
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Pulmonary Disease, Chronic Obstructive
Drug/Device/Intervention
611 300 mg Q2W
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Location
Beijing,Shenzhen,Shanghai, China
Timeline & enrollment
Phase
Phase 2
Start date
Nov 01, 2023
End date
May 01, 2025
Enrollment
150 participants
Primary outcome

Change from baseline in pre-bronchodilator FEV1 at Week 16

Summary

The primary objective of the study was to evaluate the efficacy and safety of 611 in Chinese
 adults with moderate to severe COPD.

ICD-10 classifications
Chronic obstructive pulmonary disease, unspecifiedOther chronic obstructive pulmonary diseaseOther specified chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease with acute exacerbation, unspecifiedChronic obstructive pulmonary disease with acute lower respiratory infection
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06099652
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06099652 through Pure Global AI's free database. This Phase 2 trial is sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. and is currently Not yet recruiting. The study focuses on Pulmonary Disease, Chronic Obstructive. Target enrollment is 150 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.